pre-IPO PHARMA

COMPANY OVERVIEW

Pliant Therapeutics is a clinical stage biotechnology company unraveling and targeting the key biological pathways driving fibrosis. By leveraging our powerful product discovery engine, Pliant is developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately, preserving organ function.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Fibrotic Diseases

  • WEBSITE

    https://pliantrx.com


    CAREER WEBSITE

    https://pliantrx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    agent-capital cowen-healthcare-investments eventide-asset-management menlo-ventures schroder-adveq scubed-capital third-rock-ventures


    PRESS RELEASES


    Jun 5, 2020

    Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares


    Jun 2, 2020

    Pliant Therapeutics Announces Pricing of Initial Public Offering


    Mar 23, 2020

    Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis


    Mar 3, 2020

    Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases


    Jan 8, 2020

    Pliant Therapeutics Appoints Gayle Crowell to its Board of Directors


    For More Press Releases


    Google Analytics Alternative